Publications by authors named "Pae Sangjon"

Claim this Profile
E
Efficacy and safety of a reduced starting dose of cabozantinib (20 mg) plus nivolumab for renal cell carcinoma in real-world practice.
Tomokazu Sazuka, Yuri Watanabe, Fumiya Yokochi, Kohei Toma, Yusuke Onoda, Sangjon Pae

Jpn J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consecutive real-world treatment experience with a reduced starting dose of lenvatinib (14 mg) plus pembrolizumab for metastatic renal cell carcinoma.
Tomokazu Sazuka, Kentaro Murakami, Hidetaka Nihei, Yuki Iida, Kosuke Mikami, Sangjon Pae

Jpn J Clin Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discordance between PSA level and bone metastatic volume is associated with unfavourable prognosis.
Tomoki Shirafuji, Yasutaka Yamada, Kodai Sato, Zhao Xue, Takuya Tsujino, Sangjon Pae

BJU Int· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical benefits of androgen receptor signaling inhibitors in patients with metastatic hormone-sensitive prostate cancer: real-world data from a multi-center study.
Yosuke Kinoshita, Yasutaka Yamada, Takuya Tsujino, Zhao Xue, Kodai Sato, Sangjon Pae

Jpn J Clin Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LHRH Antagonists Restore Serum Testosterone Faster Than LHRH Agonists in Prostate Cancer Patients After Radiotherapy.
Sangjon Pae, Shinichi Sakamoto, Xue Zhao, Takaaki Tamura, Tomohiko Kamasako

Prostate· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stone at the same location for 2 months predicts impacted stones and stone-free status after shock wave lithotripsy for ureteral stones: A Funabashi clinic expert study.
Kazuyoshi Nozumi, Shinichi Sakamoto, Xue Zhao, Sangjon Pae, Takaaki Tamura

Int J Urol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Machine learning analysis for detecting late recurrence and loss to follow-up after renal cell carcinoma surgery.
Kodai Sato, Tomokazu Sazuka, Takayuki Arai, Hiroaki Sato, Manato Kanesaka, Sangjon Pae

BJUI Compass· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The LAT1 inhibitor JPH203 suppresses the growth of castration-resistant prostate cancer through a CD24-mediated mechanism.
Shinpei Saito, Keisuke Ando, Shinichi Sakamoto, Minhui Xu, Yasutaka Yamada, Sangjon Pae

Cancer Sci· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Testosterone bounce predicts favorable prognoses for prostate cancer patients treated with degarelix.
Shuhei Kamada, Shinichi Sakamoto, Ryo Kinoshita, Xue Zhao, Tomohiko Kamasako, Pae Sangjon

Prostate· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Copy Number Gain in Androgen Receptors Predicts the Poor Prognosis in Japanese Castration-resistant Prostate Cancer.
Shinichi Sakamoto, Keisuke Ando, Sangjon Pae, Xue Zhao, Kazuko Sakai

Anticancer Res· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Central administered xenin induced Fos expression in nesfatin-1 neurons in rats.
Shota Saito, Hirofumi Hashimoto, Hidefumi Wakashin, Misaki Ishibane, Sangjon Pae

Brain Res Bull· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contribution of the L-Type Amino Acid Transporter Family in the Diagnosis and Treatment of Prostate Cancer.
Xue Zhao, Shinichi Sakamoto, Jiaxing Wei, Sangjon Pae, Shinpei Saito

Int J Mol Sci· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of a novel hepatitis B anti-viral drug E-CFCP in renal organic acid transporters.
Misaki Ishibane, Hirofumi Hashimoto, Meika Kaneko, Shota Saito, Sangjon Pae

J Pharmacol Sci· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting L-type amino acid transporter 1 in urological malignancy: Current status and future perspective.
Sangjon Pae, Shinichi Sakamoto, Xue Zhao, Shinpei Saito, Takaaki Tamura

J Pharmacol Sci· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[CLINICAL STUDY OF OPEN RADICAL CYSTECTOMY AND ILEAL CONDUIT CONSTRUCTION FOR BLADDER CANCER: RESULTS OF 15-YEAR SINGLE CENTER EXPERIENCE].
Toshihiro Uemura, Takehiro Ishibashi, Sangjon Pae, Norihide Shirakawa, Takatoshi Somoto

Nihon Hinyokika Gakkai Zasshi· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis